Bausch + Lomb Appoints Thomas J. Appio as Interim CEO and Expects to Raise Full-Year 2026 Adjusted EBITDA Guidance

Bausch + Lomb Corporation (NYSE: BLCO) announced the immediate appointment of Thomas J. Appio, Chairman of the Board, as interim Chief Executive Officer. This leadership change coincides with the company's expectation to raise its full-year 2026 adjusted EBITDA guidance, excluding acquired in-process research and development, based on preliminary third-quarter results. Appio will continue to serve as CEO of parent company Bausch Health.